← feed

Is NCT02422589 results overdue?

Yes — results are overdue. Primary completion was 2017-12-12; the FDAAA-801 reporting deadline (2018-12-12) passed 2748 days ago and no results are posted on ClinicalTrials.gov.

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

NCT IDNCT02422589 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-12-12 (ACTUAL)
Reporting deadline2018-12-12 (completion + 365d)
Days overdue2748
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 ea8c68ea0bb4c927… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02422589. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →